Two charts show how investors feel differently about Keryx and Acadia Pharma.
An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
TheStreet senior columnist Adam Feuerstein discusses the winners and losers from the research abstracts ahead of the ASCO cancer conference.
Here's why Stimuvax didn't help lung cancer patients live longer.
Get a head start on searching through ASCO abstracts with these 10 summaries.
New data suggests Roche's GA101 is more potent than the blockbuster Rituxan.
More than half of patients responded to treatment with Gilead's idelalisib in a phase I study.
A new class of immune-boosting drugs are showing great promise against melanoma, lung and kidney cancers.
Regulators have issued a subpoena to Spectrum for information related to the steep cut in Fusilev sales in 2013.